Fang Zhao

Publication Activity (10 Years)

Years Active: 2023-2024
Publications (10 Years): 9

Top Topics

Prognostic Factors

Top Venues

Nature medicine

Clinical cancer research : an official journal of the American Association for Cancer Research

This page only lists publications with an associated author ORCID identifier.

Publications

Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine (2024)
Martin Schuler, Kristof Cuppens, Till Plönes, Marcel Wiesweg, Bert Du Pont, Balazs Hegedus, Johannes Köster, Fabian Mairinger, Kaid Darwiche, Annette Paschen, Brigitte Maes, Michel Vanbockrijck, David Lähnemann, Fang Zhao, Hubertus Hautzel, Dirk Theegarten, Koen Hartemink, Henning Reis, Paul Baas, Alexander Schramm, Clemens Aigner
Neoadjuvant nivolumab with or without relatlimab in resectable non-small-cell lung cancer: a randomized phase 2 trial. Nature medicine 30 (6) (2024)
Renata Varaljai, Lisa Zimmer, Yahya Al-Matary, Paulien Kaptein, Lea J Albrecht, Batool Shannan, Jan C Brase, Daniel Gusenleitner, Teresa Amaral, Nina Wyss, Jochen Utikal, Lukas Flatz, Florian Rambow, Hans Christian Reinhardt, Jenny Dick, Daniel R Engel, Susanne Horn, Selma Ugurel, Wiebke Sondermann, Elisabeth Livingstone, Antje Sucker, Annette Paschen, Fang Zhao, Jan M Placke, Jasmin M Klose, Wolfgang P Fendler, Daniela S Thommen, Iris Helfrich, Dirk Schadendorf, Alexander Roesch
Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nature cancer (2023)
Renata Varaljai, Lisa Zimmer, Yahya Al-Matary, Paulien Kaptein, Lea J Albrecht, Batool Shannan, Jan C Brase, Daniel Gusenleitner, Teresa Amaral, Nina Wyss, Jochen Utikal, Lukas Flatz, Florian Rambow, Hans Christian Reinhardt, Jenny Dick, Daniel R Engel, Susanne Horn, Selma Ugurel, Wiebke Sondermann, Elisabeth Livingstone, Antje Sucker, Annette Paschen, Fang Zhao, Jan M Placke, Jasmin M Klose, Wolfgang P Fendler, Daniela S Thommen, Iris Helfrich, Dirk Schadendorf, Alexander Roesch
Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma. Nature cancer (2023)
Simone Stupia, Christina Heeke, Alicia Brüggemann, Anne Zaremba, Beatrice Thier, Julia Kretz, Antje Sucker, Manuel Philip, Gennadiy Zelinskyy, Soldano Ferrone, Alexander Roesch, Susanne Horn, Eva Hadaschik, Dirk Schadendorf, Mirko Trilling, Ulf Dittmer, Klaus Georg Griewank, Fang Zhao, Annette Paschen
HLA class II loss and JAK1/2 deficiency coevolve in melanoma leading to CD4 T cell and IFNγ cross-resistance. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)